Karan Govindpani
Overview
Explore the profile of Karan Govindpani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
347
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Snodgrass R, Govindpani K, Plant K, Kugler E, Doh C, Dawson T, et al.
Dis Model Mech
. 2023 Mar;
16(4).
PMID: 36861761
Hereditary haemorrhagic telangiectasia (HHT) causes arteriovenous malformations (AVMs) in multiple organs to cause bleeding, neurological and other complications. HHT is caused by mutations in the BMP co-receptor endoglin. We characterised...
2.
Govindpani K, Turner C, Waldvogel H, Faull R, Kwakowsky A
Int J Mol Sci
. 2020 Nov;
21(22).
PMID: 33218044
γ-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter, playing a central role in the regulation of cortical excitability and the maintenance of the excitatory/inhibitory (E/I) balance. Several lines of evidence...
3.
Vinnakota C, Govindpani K, Tate W, Peppercorn K, Anekal P, Waldvogel H, et al.
Int J Mol Sci
. 2020 May;
21(9).
PMID: 32384683
Alzheimer's disease (AD) is a progressive neurodegenerative disorder for which no cognition-restoring therapies exist. Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the brain. Increasing evidence suggests a remodeling...
4.
Govindpani K, Vinnakota C, Waldvogel H, Faull R, Kwakowsky A
Neural Regen Res
. 2019 Dec;
15(6):1030-1032.
PMID: 31823877
No abstract available.
5.
Grant P, Kahlcke N, Govindpani K, Hunter M, MacDonald C, Brimble M, et al.
Bioorg Med Chem Lett
. 2019 Oct;
29(21):126644.
PMID: 31564385
The cannabinoid-1 receptor (CB1R) inverse agonist SR141716A has proven useful for study of the endocannabinoid system, including development of divalent CB1R ligands possessing a second functional motif attached via a...
6.
Govindpani K, McNamara L, Smith N, Vinnakota C, Waldvogel H, Faull R, et al.
J Clin Med
. 2019 May;
8(5).
PMID: 31083442
Alzheimer's disease (AD) is the most prevalent form of dementia. Despite decades of research following several theoretical and clinical lines, all existing treatments for the disorder are purely symptomatic. AD...
7.
Kwakowsky A, Guzman B, Govindpani K, Waldvogel H, Faull R
Neural Regen Res
. 2018 Aug;
13(8):1362-1363.
PMID: 30106045
No abstract available.
8.
Guzman B, Vinnakota C, Govindpani K, Waldvogel H, Faull R, Kwakowsky A
J Neurochem
. 2018 Apr;
146(6):649-669.
PMID: 29645219
Glutamatergic and cholinergic dysfunction are well-attested features of Alzheimer's disease (AD), progressing with other pathological indices of the disorder and exacerbating neuronal and network dysfunction. However, relatively little attention has...
9.
Govindpani K, Guzman B, Vinnakota C, Waldvogel H, Faull R, Kwakowsky A
Int J Mol Sci
. 2017 Aug;
18(8).
PMID: 28825683
γ-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the vertebrate brain. In the past, there has been a major research drive focused on the dysfunction of the glutamatergic and...
10.
Glass M, Govindpani K, Furkert D, Hurst D, Reggio P, Flanagan J
Trends Pharmacol Sci
. 2016 Feb;
37(5):353-363.
PMID: 26917061
Bivalent ligands bridging two G-protein-coupled receptors (GPCRs) provide valuable pharmacological tools to target oligomers. The success of therapeutically targeting the cannabinoid CB1 receptor has been limited, in part due to...